

# United States Patent and Trademark Office

JhS

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
02/08/2002	02/08/2002 A. Grey Craig		3027		
6449 7590 06/06/2005		EXAMINER			
ROTHWELL, FIGG, ERNST & MANBECK, P.C.			MURPHY, JOSEPH F		
1425 K STREET, N.W. SUITE 800 WASHINGTON, DC 20005		ART UNIT	PAPER NUMBER		
		1646			
	02/08/2002 00 06/06/2005 FIGG, ERNST & MAN I, N.W.	02/08/2002 A. Grey Craig 00 06/06/2005 FIGG, ERNST & MANBECK, P.C. 1, N.W.	02/08/2002 A. Grey Craig 2314-243 00 06/06/2005 EXAM FIGG, ERNST & MANBECK, P.C. T, N.W. ART UNIT		

DATE MAILED: 06/06/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

		Ap	plication No.	Applicant(s)				
Office A - 41 - 12 Cours		10	)/067,857	CRAIG ET AL.				
	Office Action Summary	Exa	aminer	Art Unit				
			seph F. Murphy	1646				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1)⊠	1) Responsive to communication(s) filed on 3/17/2005.							
·	This action is <b>FINAL</b> . 2b) This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
<ul> <li>4)  Claim(s) 1-48 is/are pending in the application.</li> <li>4a) Of the above claim(s) 7-26, 29-48 is/are withdrawn from consideration.</li> <li>5)  Claim(s) is/are allowed.</li> <li>6)  Claim(s) 1,2,4,5,27 and 28 is/are rejected.</li> </ul>								
· ·	7)⊠ Claim(s) <u>3 and 6</u> is/are objected to. 8)□ Claim(s) are subject to restriction and/or election requirement.							
Application Papers								
<ul> <li>9) The specification is objected to by the Examiner.</li> <li>10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).</li> <li>11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.</li> </ul>								
Priority under 35 U.S.C. § 119								
<ul> <li>12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> </ul>								
* S	See the attached detailed Office action	for a list of the	e certified copies not received	d.				
Attachment	• •							
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTC	2 048)	4) Interview Summary ( Paper No(s)/Mail Dat					
3) 🔲 Inforn	nation Disclosure Statement(s) (PTO-1449 or PT r No(s)/Mail Date		5) Notice of Informal Pa		)-152)			

U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Application/Control Number: 10/067,857

Art Unit: 1646

#### **DETAILED ACTION**

#### Election/Restrictions

Applicant's election without traverse of Group I, drawn to an isolated contulakin-G comprising the amino acid sequence of SEQ ID NO: 1 in the reply filed on 3/17/2005 is acknowledged. Claims 1-6, 27-28 read on the elected Group, and are under consideration. Claims 7-26, 29-48 are withdrawn from consideration pursuant to 37 CFR 1.142(b).

#### Claim Objections

Claims 1-6, 27-28 are objected to because of the following informalities: They contain limitations drawn to non-elected subject matter. Appropriate correction is required.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-2, 4-5, 27-28 are rejected under 35 U.S.C. 103(a) as being unpatentable over U.S. Patent No. 5,700,778 (Olivera et al.) in view of Van den Steen et al. (1998).

Olivera discloses conotoxin peptides, one of which is 100% identical to SEQ ID NO: 1 of the instant application (see Sequence Comparison A, attached, please note that the X amino acid in SEQ ID NO: 1 corresponds to a Pro in the peptide disclosed in Olivera). Olivera discloses that the conotoxin peptide may be glycosylated (Column 3, lines 53-56). Olivera does not specifically disclose the Thr glycosylation. Van den Steen

Application/Control Number: 10/067,857

Art Unit: 1646

teaches the biosynthesis of O-linked sugars, (page 155, Figure 2). Van den Steen also teaches that O-linked glycosylation contributes to the specific activity of signaling molecules (page 181, column 2 to page 183 column 1) by enhancing stability and is necessary for bioactivity. Therefore it would have been obvious to one of skill in the art at the time the invention was made to produce the glycosylated peptide of Olivera with the glycosylation moiety being attached to Thr as taught in Van den Steen. The motivation is provided in Van den Steen, who teaches that glycosylation enhances stability and is necessary for bioactivity in signaling molecules.

### References

The Office will no longer be supplying paper copies of U.S. Patents cited in Office Actions. Applicant is advised that the cited U.S. patents and patent application publications are available for download via the Office's PAIR. As an alternate source, all U.S. patents and patent application publications are available on the USPTO web site (www.uspto.gov), from the Office of Public Records and from commercial sources.

Applicant may direct inquiries about the use of the Office's PAIR system to the Electronic Business Center (EBC) at http://www.uspto.gov/ebc/index.html or 1-866-217-9197.

### Conclusion

Claims 1-2, 4-5, 27-28 are rejected.

Claims 3, 6 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Art Unit: 1646

Advisory Information

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Joseph Murphy whose telephone number is (571) 272-

0877. The examiner can normally be reached Monday through Friday from 7:30 am to

5:00 pm. A message may be left on the examiner's voice mail service. If attempts to

reach the examiner by telephone are unsuccessful, the examiner's supervisor, Tony

Caputa, can be reached on (571) 272-0829.

The fax number for the organization where this application or proceeding is

assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR. Status

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

have questions on access to the Private PAIR system, contact the Electronic Business

Center (EBC) at 866-217-9197 (toll-free).

Joseph F. Murphy, Ph. D. Primary Examiner

Art Unit 1646

May 26, 2005

JOSEPH MURPHY

Page 4

MIENI EXAMINEH